Arcus Biosciences, Inc.
RCUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001724521
In the last 90 days, Arcus Biosciences, Inc. insiders filed 0 open-market purchases and 2 sales; 231 institutions reported holding it in 13F filings for Q2 2026, worth $3.78B in total; no superinvestor holds it.
Holders of 5% or more of RCUS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Arcus Biosciences, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 13D/A | 25.60%31.4M shares | −4.10 ppfrom 29.70% | Feb 20, 20254 filings | Nov 5, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 10.40%12.7M shares | +1.00 ppfrom 9.40% | Apr 17, 20252 filings | Jan 8, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
9 Schedule 13D and 13G filings on Arcus Biosciences, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20263:45 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Jan 8, 20261:28 PM ET | BlackRock, Inc. | 13G/A | 10.40%12.7M shares | +1.00 ppfrom 9.40% | Dec 31, 2025 | SEC |
| Nov 14, 20254:07 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 4.10%4.33M shares | −1.40 ppfrom 5.50%Below 5% | Sep 30, 2025 | SEC |
| Nov 5, 20255:19 PM ET | Gilead Sciences, Inc. | 13D/A | 25.60%31.4M shares | −4.10 ppfrom 29.70% | Nov 3, 2025 | SEC |
| Jul 15, 20257:46 PM ET | Gilead Sciences, Inc. | 13D/A | 29.70%31.4M shares | −5.30 ppfrom 35.00% | Jul 13, 2025 | SEC |
| May 13, 20255:57 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 5.50%5.83M shares | New | May 12, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 9.40%9.98M shares | – | Mar 31, 2025 | SEC |
| Mar 5, 20255:00 PM ET | Gilead Sciences, Inc. | 13D/A | 35.00%39.7M shares | 0.00 ppfrom 35.00% | Feb 18, 2025 | SEC |
| Feb 20, 20257:43 PM ET | Gilead Sciences, Inc. | 13D/A | 35.00%39.7M shares | – | Feb 18, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Arcus Biosciences, Inc. shares.
No Form 144 notices for Arcus Biosciences, Inc. are on file.